Nuvectis Pharma Inc. (NVCT): Price and Financial Metrics

Nuvectis Pharma Inc. (NVCT): $13.94

0.26 (+1.90%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

NVCT Price/Volume Stats

Current price $13.94 52-week high $18.65
Prev. close $13.68 52-week low $6.21
Day low $13.59 Volume 25,700
Day high $14.96 Avg. volume 55,080
50-day MA $14.40 Dividend yield N/A
200-day MA $12.99 Market Cap 240.20M

NVCT Stock Price Chart Interactive Chart >


Nuvectis Pharma Inc. (NVCT) Company Bio


Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.


NVCT Latest News Stream


Event/Time News Detail
Loading, please wait...

NVCT Latest Social Stream


Loading social stream, please wait...

View Full NVCT Social Stream

Latest NVCT News From Around the Web

Below are the latest news stories about NUVECTIS PHARMA INC that investors may wish to consider to help them evaluate NVCT as an investment opportunity.

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming scientific presentations for NXP800 at the 2023 AACR Special Conference In Cancer Research: Ovarian Cancer (October 5-7, 2023, Boston, MA) and for NXP800 and NXP900 at the 2023 AA

Yahoo | September 21, 2023

With 67% ownership, insiders at Nuvectis Pharma, Inc. (NASDAQ:NVCT) are pretty optimistic and have been buying recently

Key Insights Significant insider control over Nuvectis Pharma implies vested interests in company growth The top 4...

Yahoo | September 12, 2023

Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial

Fort Lee, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of a Phase 1a dose escalation clinical trial of NXP900, its novel inhibitor of the SRC/YES1 kinase family (“SFK”). The study is designed to evaluate the safety, tolerability

Yahoo | September 12, 2023

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ETFort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced it will host a virtual KOL event to discuss its two clinical-stage drug candidates, NXP800 and NXP900, on Thursday,

Yahoo | September 6, 2023

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Fort Lee, NJ, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences: Event H.C. Wainwright 25th Annual Global Investment Conference Date

Yahoo | September 1, 2023

Read More 'NVCT' Stories Here

NVCT Price Returns

1-mo -3.73%
3-mo -17.76%
6-mo 16.36%
1-year 77.13%
3-year N/A
5-year N/A
YTD 85.87%
2022 N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!